[Skip to Navigation]
Sign In
Views 673
Citations 0
July 13, 2020

Error in the Biomarker Subsection

JAMA Neurol. 2020;77(9):1179. doi:10.1001/jamaneurol.2020.2416

In the Original Investigation titled “Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials,” which published online November 11, 2019, and in print in February 2020 in JAMA Neurology,1 there was an error in the Biomarkers subsection of the Results section. The mean data for lanabecestat 20 mg vs placebo in DAYBREAK-ALZ was 2.2 Centiloids not −2.2 Centiloids. This article was corrected online.

Wessels  AM, Tariot  PN, Zimmer  JA,  et al.  Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials.   JAMA Neurol. 2019;77(2):199-209. doi:10.1001/jamaneurol.2019.3988PubMedGoogle ScholarCrossref